255 related articles for article (PubMed ID: 24168915)
1. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.
Kruzliak P; Novák J; Novák M
Am J Hypertens; 2014 Jan; 27(1):3-13. PubMed ID: 24168915
[TBL] [Abstract][Full Text] [Related]
2. Nitric oxide and adverse events of vascular endothelial growth factor inhibitors.
Thachil J
Curr Med Res Opin; 2011 Aug; 27(8):1503-7. PubMed ID: 21651424
[TBL] [Abstract][Full Text] [Related]
3. Use of Antihypertensive Drugs in Neoplastic Patients.
Rizzoni D; De Ciuceis C; Porteri E; Agabiti-Rosei C; Agabiti-Rosei E
High Blood Press Cardiovasc Prev; 2017 Jun; 24(2):127-132. PubMed ID: 28361339
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy.
Curwen JO; Musgrove HL; Kendrew J; Richmond GH; Ogilvie DJ; Wedge SR
Clin Cancer Res; 2008 May; 14(10):3124-31. PubMed ID: 18483380
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic-induced hypertension: the molecular basis of signaling network.
Nagai A; Sado T; Naruse K; Noguchi T; Haruta S; Yoshida S; Tanase Y; Tsunemi T; Kobayashi H
Gynecol Obstet Invest; 2012; 73(2):89-98. PubMed ID: 22222493
[TBL] [Abstract][Full Text] [Related]
6. Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress.
Lankhorst S; Kappers MH; van Esch JH; Danser AH; van den Meiracker AH
Antioxid Redox Signal; 2014 Jan; 20(1):135-45. PubMed ID: 23458507
[TBL] [Abstract][Full Text] [Related]
7. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
Launay-Vacher V; Deray G
Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1.
Lankhorst S; Kappers MH; van Esch JH; Danser AH; van den Meiracker AH
J Hypertens; 2013 Mar; 31(3):444-54; discussion 454. PubMed ID: 23221987
[TBL] [Abstract][Full Text] [Related]
9. Anti-VEGF Anticancer Drugs: Mind the Hypertension.
Katsi V; Zerdes I; Manolakou S; Makris T; Nihoyannopoulos P; Tousoulis D; Kallikazaros I
Recent Adv Cardiovasc Drug Discov; 2014; 9(2):63-72. PubMed ID: 26123049
[TBL] [Abstract][Full Text] [Related]
10. Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.
Langenberg MH; van Herpen CM; De Bono J; Schellens JH; Unger C; Hoekman K; Blum HE; Fiedler W; Drevs J; Le Maulf F; Fielding A; Robertson J; Voest EE
J Clin Oncol; 2009 Dec; 27(36):6152-9. PubMed ID: 19901116
[TBL] [Abstract][Full Text] [Related]
11. Vascular Cardio-Oncology: Vascular Endothelial Growth Factor inhibitors and hypertension.
Versmissen J; Mirabito Colafella KM; Koolen SLW; Danser AHJ
Cardiovasc Res; 2019 Apr; 115(5):904-914. PubMed ID: 30726882
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary hypertension, nitric oxide and nitric oxide-releasing compounds.
Hagan G; Pepke-Zaba J
Expert Rev Respir Med; 2011 Apr; 5(2):163-71. PubMed ID: 21510727
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis and hypertension: the dual role of anti-hypertensive and anti-angiogenic therapies.
Ferroni P; Della-Morte D; Palmirotta R; Rundek T; Guadagni F; Roselli M
Curr Vasc Pharmacol; 2012 Jul; 10(4):479-93. PubMed ID: 22272903
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension.
Kruzliak P; Kovacova G; Pechanova O
Angiogenesis; 2013 Apr; 16(2):289-95. PubMed ID: 23203441
[TBL] [Abstract][Full Text] [Related]
15. Management of hypertension in angiogenesis inhibitor-treated patients.
Izzedine H; Ederhy S; Goldwasser F; Soria JC; Milano G; Cohen A; Khayat D; Spano JP
Ann Oncol; 2009 May; 20(5):807-15. PubMed ID: 19150949
[TBL] [Abstract][Full Text] [Related]
16. High intraocular pressure following anti-vascular endothelial growth factor therapy: proposed pathophysiology due to altered nitric oxide metabolism.
Ricca AM; Morshedi RG; Wirostko BM
J Ocul Pharmacol Ther; 2015 Feb; 31(1):2-10. PubMed ID: 25369256
[TBL] [Abstract][Full Text] [Related]
17. Anti-vascular endothelial growth factor therapy in the era of personalized medicine.
Féliz LR; Tsimberidou AM
Cancer Chemother Pharmacol; 2013 Jul; 72(1):1-12. PubMed ID: 23463481
[TBL] [Abstract][Full Text] [Related]
18. Etiology of angiogenesis inhibition-related hypertension.
Lankhorst S; Saleh L; Danser AJ; van den Meiracker AH
Curr Opin Pharmacol; 2015 Apr; 21():7-13. PubMed ID: 25500206
[TBL] [Abstract][Full Text] [Related]
19. Treatment Of Sunitinib-Induced Hypertension In Solid Tumors By Nitric Oxid Donors.
Leon LA; Antón-Aparicio LM
Redox Biol; 2015 Aug; 5():422. PubMed ID: 28162293
[TBL] [Abstract][Full Text] [Related]
20. The role of vascular endothelial growth factor in pulmonary arterial hypertension. The angiogenesis paradox.
Voelkel NF; Gomez-Arroyo J
Am J Respir Cell Mol Biol; 2014 Oct; 51(4):474-84. PubMed ID: 24932885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
